Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

doi:10.1186/s12885-024-13074-z

Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors

Tirtha Mandal & Maloy Ghosh et al. · 2024-11-07

1Citations

Links

DOI PubMed

Journal

BMC Cancer

TL;DR

This study provides a foundation for utilizing LLT1 as a potential target to improve clinical responses in ICI non-responsive patients with upregulated LLT1 and shows a correlation of upregulated LLT1 with multiple immunosuppressive genes in patients non-responsive to current ICIs.

AI-generated by Semantic Scholar

Authors

Tirtha Mandal, Soorya Gnanasegaran, Golding Rodrigues, Shalini Kashipathi, Anurag Tiwari, Ashvini Kumar Dubey, Sanghamitra Bhattacharjee, Yogendra Manjunath, Subith Krishna, M. S. Madhusudhan, Maloy Ghosh